Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum

      (PRNewsfoto/Medtronic plc)

      News provided by

      Medtronic plc

      Nov 18, 2025, 06:45 ET

      Share this article

      Share this article


      Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance

      GALWAY, Ireland, Nov. 18, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025.

      Q2 Key Highlights

      Continue Reading
      Medtronic reports strong second quarter fiscal 2026 financial results
      View PDF
      Medtronic reports strong second quarter fiscal 2026 financial results
      Medtronic reports strong second quarter fiscal 2026 financial results
      View PDF
      Medtronic reports strong second quarter fiscal 2026 financial results
      Medtronic reports strong second quarter fiscal 2026 financial results
      Medtronic reports strong second quarter fiscal 2026 financial results

      • Revenue of $9.0 billion, increased 6.6% as reported and 5.5% organic, 75 basis points above guidance midpoint

      • GAAP diluted EPS of $1.07 increased 8%; non-GAAP diluted EPS of $1.36 increased 8%, above guidance

      • Raising FY26 guidance: 5.5% organic revenue growth, $5.62-$5.66 adjusted EPS

      • Strongest Cardiovascular revenue growth in over a decade, excluding pandemic

      • Cardiac Ablation Solutions revenue increased 71%, including 128% in the U.S., on strength of pulsed field ablation (PFA) portfolio

      • Received broad, favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) and several favorable commercial payer coverage policies for the Symplicity™ procedure for the treatment of uncontrolled hypertension, or high blood pressure, with U.S. addressable market of 18 million people

      • Secured U.S. FDA approval for the Altaviva™ device, a simple option for treating urge urinary incontinence, which affects over 16 million people in the U.S.

      • Hugo™ robotic-assisted surgery system Enable Hernia Repair study met safety and effectiveness endpoints; initiated Embrace Gynecology US pivotal study

      • U.S. FDA cleared the MiniMed™ 780G system to enable integration with the Instinct sensor and approved use of the MiniMed™ 780G system in Type 2 diabetes

      "We delivered a strong second quarter, with both revenue and EPS beating expectations. Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic chairman and chief executive officer. "Looking ahead, we are positioned for even greater acceleration of revenue growth in the back half of the year and beyond, driven by several enterprise growth drivers, including our PFA franchise for Afib, Symplicity™ procedure for hypertension, Hugo™ robotic-assisted surgery system, and Altaviva™ therapy for urge urinary incontinence."

      Financial Results
      Medtronic reported Q2 worldwide revenue of $8.961 billion, an increase of 6.6% as reported and 5.5% on an organic basis. The organic revenue growth comparison excludes:

      • Other revenue of $35 million in the current year and $37 million in the prior year;

      • Revenue from the Dutch Obesity Clinic (NOK) divestiture of $5 million in the current year and $16 million in the prior year; and

      • Foreign exchange benefit of $111 million on the remaining segments.

      Q2 revenue by segment included:

      • Cardiovascular Portfolio revenue of $3.436 billion, an increase of 10.8% as reported and 9.3% organic, with a mid-teens increase in Cardiac Rhythm & Heart Failure, high-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis;

      • Neuroscience Portfolio revenue of $2.562 billion, an increase of 4.5% reported and 3.9% organic, with a high-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal Technologies, and flat result in Specialty Therapies, all on an organic basis;

      • Medical Surgical Portfolio revenue of $2.171 billion, an increase of 2.1% as reported and 1.3% organic, with low-single digit organic increases in both Surgical & Endoscopy and Acute Care & Monitoring; and

      • Diabetes business revenue of $757 million, an increase of 10.3% as reported and 7.1% organic.

      Q2 GAAP operating profit and operating margin were $1.686 billion and 18.8%, respectively, an increase of 6% and a decrease of 20 basis points, respectively. As detailed in the financial schedules included at the end of the release, Q2 non-GAAP operating profit and operating margin were $2.162 billion and 24.1%, respectively, an increase of 6% and a decrease of 20 basis points, respectively.

      Q2 GAAP net income and diluted earnings per share (EPS) were $1.374 billion and $1.07, respectively, both increases of 8%. As detailed in the financial schedules included at the end of this release, Q2 non-GAAP net income and non-GAAP diluted EPS were $1.746 billion and $1.36, respectively, both increases of 8%.

      Guidance
      The company today raised its FY26 revenue growth and EPS guidance.

      The company raised its FY26 organic revenue growth guidance to approximately 5.5%, an increase from the prior guidance of approximately 5.0%.

      The company raised its FY26 diluted non-GAAP EPS guidance to the new range of $5.62 to $5.66 versus the prior $5.60 to $5.66. This includes a potential impact from tariffs of approximately $185 million, unchanged from the prior guidance. Excluding the potential impact from tariffs, this guidance represents FY26 diluted non-GAAP EPS growth of approximately 4.5%.

      "In the second quarter, we drove underlying efficiency gains in our gross margin, significantly increased R&D to fuel our future growth, as well as strategically increased investment in sales and marketing for our growth programs in light of the outsized demand and building momentum for key programs," said Thierry Piéton, Medtronic chief financial officer. "Given our outperformance in the first half of the year and confidence we have in our revenue growth acceleration, we are raising today our full year revenue and EPS guidance."

      Video Webcast Information
      Medtronic will host a video webcast today, November 18, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com.

      Financial Schedules and Earnings Presentation
      The second quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the second quarter earnings presentation, click here.

      About Medtronic
      Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission -- to alleviate pain, restore health, and extend life -- unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.

      FORWARD LOOKING STATEMENTS
      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.

      NON-GAAP FINANCIAL MEASURES
      This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2025, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis.

      Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.

      Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

      Contacts:
      Erika Winkels
      Public Relations
      +1-763-526-8478

      Ryan Weispfenning
      Investor Relations
      +1-763-505-4626

      MEDTRONIC PLC

      WORLD WIDE REVENUE(1)

      (Unaudited)



      SECOND QUARTER



      YEAR-TO-DATE


      REPORTED




      ORGANIC



      REPORTED




      ORGANIC

      (in millions)

      FY26


      FY25


      Growth


      Currency
      Impact(4)


      FY26(5)


      FY25(5)


      Growth



      FY26


      FY25


      Growth


      Currency
      Impact(4)


      FY26(6)


      FY25(6)


      Growth

      Cardiovascular

      $     3,436


      $  3,102


      10.8 %


      $         46


      $     3,390


      $     3,102


      9.3 %



      $     6,721


      $     6,108


      10.0 %


      $        114


      $     6,607


      $     6,108


      8.2 %

      Cardiac Rhythm & Heart Failure

      1,825


      1,578


      15.7


      22


      1,804


      1,578


      14.3



      3,538


      3,114


      13.6


      58


      3,479


      3,114


      11.7

      Structural Heart & Aortic

      956


      881


      8.5


      17


      939


      881


      6.6



      1,885


      1,736


      8.6


      39


      1,847


      1,736


      6.4

      Coronary & Peripheral Vascular

      655


      643


      1.9


      7


      648


      643


      0.8



      1,298


      1,259


      3.1


      17


      1,281


      1,259


      1.8

      Neuroscience

      2,562


      2,451


      4.5


      15


      2,546


      2,451


      3.9



      4,978


      4,768


      4.4


      43


      4,935


      4,768


      3.5

      Cranial & Spinal Technologies

      1,299


      1,234


      5.2


      6


      1,293


      1,234


      4.7



      2,509


      2,382


      5.4


      18


      2,492


      2,382


      4.6

      Specialty Therapies

      744


      737


      0.9


      5


      739


      737


      0.3



      1,446


      1,450


      (0.3)


      13


      1,432


      1,450


      (1.2)

      Neuromodulation

      520


      480


      8.3


      5


      515


      480


      7.3



      1,023


      937


      9.2


      12


      1,011


      937


      7.9

      Medical Surgical

      2,171


      2,128


      2.1


      27


      2,139


      2,111


      1.3



      4,255


      4,123


      3.2


      67


      4,183


      4,107


      1.8

      Surgical & Endoscopy

      1,679


      1,649


      1.8


      23


      1,651


      1,633


      1.1



      3,291


      3,193


      3.0


      55


      3,231


      3,177


      1.7

      Acute Care & Monitoring

      493


      478


      3.0


      4


      488


      478


      2.0



      964


      930


      3.6


      12


      952


      930


      2.3

      Diabetes

      757


      686


      10.3


      22


      735


      686


      7.1



      1,478


      1,333


      10.9


      45


      1,433


      1,333


      7.5

      Total Reportable Segments

      8,926


      8,366


      6.7


      111


      8,811


      8,350


      5.5



      17,432


      16,333


      6.7


      270


      17,158


      16,317


      5.2

      Other(2)

      35


      37


      (5.8)


      --


      --


      --


      --



      107


      (15)


      NM(3)


      3


      --


      --


      --

      TOTAL

      $     8,961


      $  8,403


      6.6 %


      $        111


      $     8,811


      $     8,350


      5.5 %



      $   17,539


      $   16,318


      7.5 %


      $        273


      $   17,158


      $   16,317


      5.2 %



      (1)

      The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

      (2)

      Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.

      (3)

      Not meaningful (NM).

      (4)

      The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

      (5)

      The three months ended October 24, 2025 excludes $151 million of revenue adjustments, including $35 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $111 million of favorable currency impact on the remaining segments. The three months ended October 25, 2024 excludes $53 million of revenue adjustments, including $37 million of inorganic revenue related to the transition activity noted in (2) and $16 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

      (6)

      The six months ended October 24, 2025 excludes $382 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $68 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $270 million of favorable currency impact on the remaining segments. The six months ended October 25, 2024 excludes $1 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $75 million of inorganic revenue related to the transition activity noted in (2), and $16 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

      MEDTRONIC PLC

      U.S. REVENUE(1)(2)

      (Unaudited)



      SECOND QUARTER



      YEAR-TO-DATE


      REPORTED


      ORGANIC



      REPORTED


      ORGANIC

      (in millions)

      FY26


      FY25


      Growth


      FY26


      FY25


      Growth



      FY26


      FY25


      Growth


      FY26


      FY25


      Growth

      Cardiovascular

      $     1,592


      $     1,434


      11.0 %


      $     1,592


      $     1,434


      11.0 %



      $     3,071


      $     2,836


      8.3 %


      $     3,071


      $     2,836


      8.3 %

      Cardiac Rhythm & Heart Failure

      920


      768


      19.9


      920


      768


      19.9



      1,754


      1,534


      14.4


      1,754


      1,534


      14.4

      Structural Heart & Aortic

      390


      388


      0.4


      390


      388


      0.4



      761


      757


      0.6


      761


      757


      0.6

      Coronary & Peripheral Vascular

      282


      278


      1.4


      282


      278


      1.4



      556


      546


      1.7


      556


      546


      1.7

      Neuroscience

      1,730


      1,677


      3.1


      1,730


      1,677


      3.1



      3,354


      3,242


      3.4


      3,354


      3,242


      3.4

      Cranial & Spinal Technologies

      966


      926


      4.4


      966


      926


      4.4



      1,857


      1,781


      4.2


      1,857


      1,781


      4.2

      Specialty Therapies

      409


      418


      (2.2)


      409


      418


      (2.2)



      801


      816


      (1.8)


      801


      816


      (1.8)

      Neuromodulation

      355


      333


      6.4


      355


      333


      6.4



      695


      645


      7.9


      695


      645


      7.9

      Medical Surgical

      943


      944


      (0.1)


      943


      944


      (0.1)



      1,827


      1,825


      0.1


      1,827


      1,825


      0.1

      Surgical & Endoscopy

      665


      675


      (1.5)


      665


      675


      (1.5)



      1,286


      1,304


      (1.4)


      1,286


      1,304


      (1.4)

      Acute Care & Monitoring

      278


      269


      3.4


      278


      269


      3.4



      541


      521


      3.9


      541


      521


      3.9

      Diabetes

      230


      232


      (0.8)


      230


      232


      (0.8)



      447


      447


      --


      447


      447


      --

      Total Reportable Segments

      4,494


      4,286


      4.8


      4,494


      4,286


      4.8



      8,699


      8,350


      4.2


      8,699


      8,350


      4.2

      Other(3)

      22


      18


      21.9


      --


      --


      --



      42


      37


      14.1


      --


      --


      --

      TOTAL

      $     4,516


      $     4,304


      4.9 %


      $     4,494


      $     4,286


      4.8 %



      $     8,741


      $     8,387


      4.2 %


      $     8,699


      $     8,350


      4.2 %



      (1)

      U.S. includes the United States and U.S. territories.

      (2)

      The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

      (3)

      Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested.

      MEDTRONIC PLC

      INTERNATIONAL REVENUE(1)

      (Unaudited)



      SECOND QUARTER



      YEAR-TO-DATE


      REPORTED




      ORGANIC



      REPORTED




      ORGANIC

      (in millions)

      FY26


      FY25


      Growth


      Currency
      Impact(4)


      FY26(5)


      FY25(5)


      Growth



      FY26


      FY25


      Growth


      Currency
      Impact(4)


      FY26(6)


      FY25(6)


      Growth

      Cardiovascular

      $     1,844


      $     1,668


      10.6 %


      $         46


      $     1,799


      $     1,668


      7.8 %



      $     3,650


      $     3,272


      11.6 %


      $        114


      $     3,536


      $     3,272


      8.1 %

      Cardiac Rhythm & Heart Failure

      905


      811


      11.7


      22


      883


      811


      9.0



      1,784


      1,580


      12.9


      58


      1,725


      1,580


      9.2

      Structural Heart & Aortic

      566


      492


      14.9


      17


      549


      492


      11.5



      1,124


      980


      14.8


      39


      1,085


      980


      10.8

      Coronary & Peripheral Vascular

      373


      365


      2.3


      7


      366


      365


      0.3



      743


      713


      4.2


      17


      726


      713


      1.8

      Neuroscience

      832


      774


      7.5


      15


      817


      774


      5.5



      1,624


      1,526


      6.4


      43


      1,582


      1,526


      3.6

      Cranial & Spinal Technologies

      332


      308


      7.8


      6


      326


      308


      5.9



      652


      600


      8.7


      18


      635


      600


      5.8

      Specialty Therapies

      335


      319


      4.9


      5


      330


      319


      3.5



      644


      634


      1.6


      13


      631


      634


      (0.4)

      Neuromodulation

      165


      146


      12.7


      5


      160


      146


      9.2



      328


      292


      12.3


      12


      316


      292


      8.1

      Medical Surgical

      1,228


      1,183


      3.8


      27


      1,196


      1,167


      2.5



      2,427


      2,298


      5.6


      67


      2,356


      2,282


      3.2

      Surgical & Endoscopy

      1,014


      974


      4.1


      23


      987


      958


      3.0



      2,004


      1,889


      6.1


      55


      1,945


      1,873


      3.9

      Acute Care & Monitoring

      214


      209


      2.5


      4


      210


      209


      0.3



      423


      409


      3.3


      12


      411


      409


      0.3

      Diabetes

      527


      455


      16.0


      22


      505


      455


      11.1



      1,031


      886


      16.4


      45


      986


      886


      11.2

      Total Reportable Segments

      4,432


      4,080


      8.6


      111


      4,317


      4,064


      6.2



      8,733


      7,983


      9.4


      270


      8,459


      7,966


      6.2

      Other(2)

      13


      19


      (32.4)


      --


      --


      --


      --



      65


      (51)


      NM(3)  


      3


      --


      --


      --

      TOTAL

      $     4,445


      $     4,099


      8.4 %


      $        111


      $     4,317


      $     4,064


      6.2 %



      $     8,799


      $     7,931


      10.9 %


      $        273


      $     8,459


      $     7,966


      6.2 %



      (1)

      The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

      (2)

      Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.

      (3)

      Not meaningful (NM).

      (4)

      The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.

      (5)

      The three months ended October 24, 2025 excludes $128 million of revenue adjustments, including $13 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $111 million of favorable currency impact on the remaining segments. The three months ended October 25, 2024 excludes $35 million of revenue adjustments, including $19 million of inorganic revenue related to the transition activity noted in (2) and $16 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

      (6)

      The six months ended October 24, 2025 excludes $340 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $27 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $270 million of favorable currency impact on the remaining segments. The six months ended October 25, 2024 excludes $35 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $38 million of inorganic revenue related to the transition activity noted in (2), and $16 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.

      MEDTRONIC PLC

      CONSOLIDATED STATEMENTS OF INCOME

      (Unaudited) 



      Three months ended


      Six months ended

      (in millions, except per share data)

      October 24, 2025


      October 25, 2024


      October 24, 2025


      October 25, 2024

      Net sales

      $              8,961


      $              8,403


      $           17,539


      $           16,318

      Costs and expenses:








      Cost of products sold, excluding amortization of intangible assets

      3,061


      2,946


      6,062


      5,707

      Research and development expense

      754


      697


      1,480


      1,373

      Selling, general, and administrative expense

      2,965


      2,757


      5,772


      5,412

      Amortization of intangible assets

      463


      413


      922


      827

      Restructuring charges, net

      10


      30


      55


      77

      Certain litigation charges, net

      --


      --


      27


      81

      Other operating expense (income), net

      22


      (34)


      92


      (33)

      Operating profit

      1,686


      1,595


      3,130


      2,873

      Other non-operating income, net

      (92)


      (173)


      (125)


      (330)

      Interest expense, net

      181


      209


      357


      376

      Income before income taxes

      1,597


      1,559


      2,898


      2,827

      Income tax provision

      215


      281


      470


      500

      Net income

      1,381


      1,278


      2,428


      2,327

      Net income attributable to noncontrolling interests

      (7)


      (9)


      (14)


      (15)

      Net income attributable to Medtronic

      $              1,374


      $              1,270


      $             2,414


      $             2,312

      Basic earnings per share

      $                1.07


      $                0.99


      $               1.88


      $               1.79

      Diluted earnings per share

      $                1.07


      $                0.99


      $               1.87


      $               1.79

      Basic weighted average shares outstanding

      1,282.0


      1,282.4


      1,281.8


      1,288.6

      Diluted weighted average shares outstanding

      1,288.0


      1,286.9


      1,287.5


      1,292.5


      The data in the schedule above has been intentionally rounded to the nearest million.

      MEDTRONIC PLC

      GAAP TO NON-GAAP RECONCILIATIONS(1)

      (Unaudited) 



      Three months ended October 24, 2025

      (in millions, except per share data)

      Net
      Sales


      Cost of
      Products
      Sold


      Gross
      Margin
      Percent


      Operating
      Profit


      Operating
      Profit
      Percent


      Income
      Before
      Income
      Taxes


      Net Income
      attributable
      to
      Medtronic


      Diluted
      EPS


      Effective
      Tax Rate

      GAAP

      $  8,961


      $   3,061


      65.8 %


      $     1,686


      18.8 %


      $    1,597


      $       1,374


      $     1.07


      13.5 %

      Non-GAAP Adjustments:


















      Amortization of intangible assets(2)

      --


      --


      --


      463


      5.2


      463


      376


      0.29


      18.8

      Restructuring and associated costs(3)

      --


      --


      --


      13


      0.1


      13


      9


      0.01


      23.1

      Acquisition and divestiture-related items(4)

      --


      (9)


      0.1


      --


      --


      --


      (8)


      (0.01)


      --

      (Gain)/loss on minority investments(5)

      --


      --


      --


      --


      --


      24


      24


      0.02


      --

      Certain tax adjustments, net(6)

      --


      --


      --


      --


      --


      --


      (29)


      (0.02)


      --

      Non-GAAP

      $  8,961


      $   3,052


      65.9 %


      $     2,162


      24.1 %


      $    2,097


      $       1,746


      $     1.36


      16.4 %

      Currency impact

      (111)


      50


      (1.0)


      (93)


      (0.7)






      (0.06)



      Currency Adjusted

      $  8,850


      $   3,102


      64.9 %


      $     2,070


      23.4 %






      $     1.30






















      Three months ended October 25, 2024

      (in millions, except per share data)

      Net
      Sales


      Cost of
      Products
      Sold


      Gross
      Margin
      Percent


      Operating
      Profit


      Operating
      Profit
      Percent


      Income
      Before
      Income
      Taxes


      Net Income
      attributable
      to
      Medtronic


      Diluted
      EPS


      Effective
      Tax Rate

      GAAP

      $  8,403


      $   2,946


      64.9 %


      $     1,595


      19.0 %


      $    1,559


      $       1,270


      $     0.99


      18.0 %

      Non-GAAP Adjustments:


















      Amortization of intangible assets

      --


      --


      --


      413


      4.9


      413


      338


      0.26


      18.2

      Restructuring and associated costs(3)

      --


      (11)


      0.1


      46


      0.5


      46


      37


      0.03


      19.6

      Acquisition and divestiture-related items(4)

      --


      (5)


      0.1


      (25)


      (0.3)


      (25)


      (30)


      (0.02)


      (20.0)

      (Gain)/loss on minority investments(5)

      --


      --


      --


      --


      --


      (10)


      (21)


      (0.02)


      (100.0)

      Medical device regulations(7)

      --


      (9)


      0.1


      12


      0.1


      12


      10


      0.01


      16.7

      Certain tax adjustments, net

      --


      --


      --


      --


      --


      --


      16


      0.01


      --

      Non-GAAP

      $  8,403


      $   2,921


      65.2 %


      $     2,041


      24.3 %


      $    1,995


      $       1,620


      $     1.26


      18.3 %



      See description of non-GAAP financial measures contained in the press release dated November 18, 2025.

      (1)

      The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

      (2)

      The Company recognized $46 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.

      (3)

      The charges primarily relate to employee termination benefits and facility related and contract termination costs.

      (4)

      The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.

      (5)

      We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

      (6)

      Primarily includes a tax benefit recognized due to a change in interest accrued on uncertain tax positions, partially offset by amortization of previously established deferred tax assets arising from intercompany intellectual property transactions.

      (7)

      The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs.

      MEDTRONIC PLC

      GAAP TO NON-GAAP RECONCILIATIONS(1)

      (Unaudited) 



      Six months ended October 24, 2025

      (in millions, except per share data)

      Net
      Sales


      Cost of
      Products
      Sold


      Gross
      Margin
      Percent


      Operating
      Profit


      Operating
      Profit
      Percent


      Income
      Before
      Income
      Taxes


      Net Income
      attributable
      to Medtronic


      Diluted
      EPS


      Effective
      Tax Rate

      GAAP

      $ 17,539


      $   6,062


      65.4 %


      $     3,130


      17.8 %


      $    2,898


      $         2,414


      $     1.87


      16.2 %

      Non-GAAP Adjustments:


















      Amortization of intangible assets(2)

      --


      --


      --


      922


      5.4


      922


      750


      0.58


      18.7

      Restructuring and associated costs(3)

      --


      (16)


      0.1


      79


      0.5


      79


      61


      0.05


      24.1

      Acquisition and divestiture-related items(4)

      --


      (16)


      0.1


      58


      0.3


      58


      40


      0.03


      31.0

      Certain litigation charges, net

      --


      --


      --


      27


      0.2


      27


      21


      0.02


      22.2

      (Gain)/loss on minority investments(5)

      --


      --


      --


      --


      --


      137


      130


      0.10


      5.1

      Other(6)

      (39)


      --


      (0.2)


      (39)


      (0.2)


      (39)


      (30)


      (0.02)


      20.5

      Certain tax adjustments, net(7)

      --


      --


      --


      --


      --


      --


      (13)


      (0.01)


      --

      Non-GAAP

      $ 17,501


      $   6,031


      65.5 %


      $     4,179


      23.9 %


      $    4,084


      $         3,372


      $     2.62


      17.1 %

      Currency impact

      (270)


      4


      (0.5)


      (103)


      (0.2)






      (0.06)



      Currency Adjusted

      $ 17,230


      $   6,035


      65.0 %


      $     4,076


      23.7 %






      $     2.56






















      Six months ended October 25, 2024

      (in millions, except per share data)

      Net
      Sales


      Cost of
      Products
      Sold


      Gross
      Margin
      Percent


      Operating
      Profit


      Operating
      Profit
      Percent


      Income
      Before
      Income
      Taxes


      Net Income
      attributable
      to Medtronic


      Diluted
      EPS


      Effective
      Tax Rate

      GAAP

      $ 16,318


      $   5,707


      65.0 %


      $     2,873


      17.6 %


      $    2,827


      $         2,312


      $     1.79


      17.7 %

      Non-GAAP Adjustments:


















      Amortization of intangible assets

      --


      --


      --


      827


      4.9


      827


      678


      0.52


      18.0

      Restructuring and associated costs(3)

      --


      (20)


      0.1


      108


      0.6


      108


      87


      0.07


      19.4

      Acquisition and divestiture-related items(4)

      --


      (16)


      0.1


      (13)


      (0.1)


      (13)


      (19)


      (0.01)


      (46.2)

      Certain litigation charges, net

      --


      --


      --


      81


      0.5


      81


      68


      0.05


      16.0

      (Gain)/loss on minority investments(5)

      --


      --


      --


      --


      --


      (27)


      (38)


      (0.03)


      (37.0)

      Medical device regulations(8)

      --


      (20)


      0.1


      27


      0.2


      27


      22


      0.02


      18.5

      Other(6)

      90


      --


      0.4


      90


      0.5


      90


      70


      0.05


      22.2

      Certain tax adjustments, net(7)

      --


      --


      --


      --


      --


      --


      33


      0.03


      --

      Non-GAAP

      $ 16,408


      $   5,651


      65.6 %


      $     3,993


      24.3 %


      $    3,921


      $         3,213


      $     2.49


      17.7 %



      See description of non-GAAP financial measures contained in the press release dated November 18, 2025.

      (1)

      The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.

      (2)

      The Company recognized $91 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.

      (3)

      The charges primarily relate to employee termination benefits and facility related and contract termination costs.

      (4)

      The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.

      (5)

      We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

      (6)

      Reflects adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.

      (7)

      The net benefit for the six months ended October 24, 2025 primarily includes a tax benefit recognized due to a change in interest accrued on uncertain tax positions, partially offset by amortization of previously established deferred tax assets arising from intercompany intellectual property transactions. The charges for the six months ended October 25, 2024 primarily includes amortization of previously established deferred tax assets arising from intercompany intellectual property transactions.

      (8)

      The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs.

      MEDTRONIC PLC

      GAAP TO NON-GAAP RECONCILIATIONS(1)

      (Unaudited) 



      Three months ended October 24, 2025

      (in millions)

      Net Sales


      SG&A
      Expense


      SG&A
      Expense as
      a % of Net
      Sales


      R&D
      Expense


      R&D
      Expense
      as a % of
      Net Sales


      Other
      Operating
      (Income)
      Expense,
      net


      Other
      Operating
      (Inc.)/Exp.,
      net as a % of
      Net Sales


      Other Non-
      Operating
      Income, net

      GAAP

      $      8,961


      $     2,965


      33.1 %


      $       754


      8.4 %


      $           22


      0.2 %


      $           (92)

      Non-GAAP Adjustments:
















      Restructuring and associated costs(2)

      --


      (3)


      --


      --


      --


      --


      --


      --

      Acquisition and divestiture-related items(3)

      --


      (35)


      (0.4)


      --


      --


      43


      0.5


      --

      (Gain)/loss on minority investments(4)

      --


      --


      --


      --


      --


      --


      --


      (24)

      Non-GAAP

      $      8,961


      $     2,927


      32.7 %


      $       755


      8.4 %


      $           64


      0.7 %


      $          (116)


















      Six months ended October 24, 2025

      (in millions)

      Net Sales


      SG&A
      Expense


      SG&A
      Expense as
      a % of Net
      Sales


      R&D
      Expense


      R&D
      Expense
      as a % of
      Net Sales


      Other
      Operating
      (Income)
      Expense,
      net


      Other
      Operating
      (Inc.)/Exp.,
      net as a % of
      Net Sales


      Other Non-
      Operating
      Income, net

      GAAP

      $    17,539


      $     5,772


      32.9 %


      $    1,480


      8.4 %


      $           92


      0.5 %


      $          (125)

      Non-GAAP Adjustments:
















      Restructuring and associated costs(2)

      --


      (8)


      --


      --


      --


      --


      --


      --

      Acquisition and divestiture-related items(3)

      --


      (61)


      (0.3)


      --


      --


      18


      0.1


      --

      Other(5)

      (39)


      --


      --


      --


      --


      --


      --


      --

      (Gain)/loss on minority investments(4)

      --


      --


      --


      --


      --


      --


      --


      (137)

      Non-GAAP

      $    17,501


      $     5,702


      32.6 %


      $    1,480


      8.5 %


      $         108


      0.6 %


      $          (262)



      See description of non-GAAP financial measures contained in the press release dated November 18, 2025.

      (1)

      The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

      (2)

      The charges primarily relate to employee termination benefits and facility related and contract termination costs.

      (3)

      The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and a gain related to a certain business sale. Exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.

      (4)

      We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.

      (5)

      Reflects adjustments to the Company's Italian payback accruals resulting from the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.

      MEDTRONIC PLC

      GAAP TO NON-GAAP RECONCILIATIONS(1)

      (Unaudited)



      Six months ended

      (in millions)

      October 24, 2025


      October 25, 2024

      Net cash provided by operating activities

      $                      2,013


      $                      1,944

      Additions to property, plant, and equipment

      (972)


      (924)

      Free Cash Flow(2)

      $                      1,041


      $                      1,020



      See description of non-GAAP financial measures contained in the press release dated November 18, 2025.

      (1)

      The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

      (2)

      Free cash flow represents operating cash flows less property, plant, and equipment additions.

      MEDTRONIC PLC

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (Unaudited)



      Six months ended

      (in millions)

      October 24, 2025


      October 25, 2024

      Operating Activities:




      Net income

      $                2,428


      $                2,327

      Adjustments to reconcile net income to net cash provided by operating activities:




      Depreciation and amortization

      1,493


      1,337

      Provision for credit losses

      66


      45

      Deferred income taxes

      160


      57

      Stock-based compensation

      268


      242

      Other, net

      167


      (98)

      Change in operating assets and liabilities, net of acquisitions and divestitures:




      Accounts receivable, net

      74


      (181)

      Inventories

      (672)


      (278)

      Accounts payable and accrued liabilities

      (780)


      (707)

      Other operating assets and liabilities

      (1,191)


      (800)

      Net cash provided by operating activities

      2,013


      1,944

      Investing Activities:




      Additions to property, plant, and equipment

      (972)


      (924)

      Purchases of investments

      (4,201)


      (4,019)

      Sales and maturities of investments

      3,958


      4,338

      Other investing activities, net

      14


      1

      Net cash used in investing activities

      (1,201)


      (604)

      Financing Activities:




      Change in current debt obligations, net

      1,402


      (67)

      Issuance of long-term debt

      1,747


      3,209

      Payments on long-term debt

      (2,930)


      --

      Dividends to shareholders

      (1,820)


      (1,795)

      Issuance of ordinary shares

      255


      232

      Repurchase of ordinary shares

      (495)


      (2,780)

      Other financing activities, net

      65


      (64)

      Net cash used in financing activities

      (1,776)


      (1,265)

      Effect of exchange rate changes on cash and cash equivalents

      28


      35

      Net change in cash and cash equivalents

      (936)


      110

      Cash and cash equivalents at beginning of period

      2,218


      1,284

      Cash and cash equivalents at end of period

      $                1,282


      $                1,394





      Supplemental Cash Flow Information




      Cash paid for:




         Income taxes

      $                1,394


      $                1,335

         Interest

      542


      513


      The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.

      SOURCE Medtronic plc

      Modal title

      Organization Profile

      Medtronic plc

        Also from this source

      • Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

      • Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years

      • Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.